Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PEG-immunoliposome.

Kazuo Maruyama1

  • 1School of Pharmaceutical Sciences, Teikyo University, Sagamiko, Tsukui-gun, Kanagawa, Japan. maruyama@pharm.teikyo-u.ac.jp

Bioscience Reports
|November 14, 2002
PubMed
Summary
This summary is machine-generated.

Newly developed PEG-immunoliposomes (Type C) show enhanced targeting to lung endothelium and solid tumors. These liposomes demonstrate improved accumulation in tumors and reduced RES uptake, highlighting their potential for targeted drug delivery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coagulation and Fibrinolysis Profiles in Mouse Breast Cancer 4T1 Tumor-Bearing Mice: A Characterization of Neutrophil-Associated Prothrombotic States.

Biological & pharmaceutical bulletin·2025
Same author

Phosphorodiamidate Morpholino Oligomers-Loaded Nanobubbles for Ultrasound-Mediated Delivery to the Myocardium in Muscular Dystrophy.

ACS omega·2025
Same author

C-C Motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator.

Cardiovascular research·2024
Same author

Brain Delivery of Cisplatin Using Microbubbles in Combination with Ultrasound as an Effective Therapy for Glioblastoma.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

Development of a Gene and Nucleic Acid Delivery System for Skeletal Muscle Administration via Limb Perfusion Using Nanobubbles and Ultrasound.

Pharmaceutics·2023
Same author

Development of an Antibody Delivery Method for Cancer Treatment by Combining Ultrasound with Therapeutic Antibody-Modified Nanobubbles Using Fc-Binding Polypeptide.

Pharmaceutics·2023
Same journal

Bacterial heteroresistance mechanisms, dynamics, and emerging diagnostic approaches.

Bioscience reports·2026
Same journal

Expression of Concern: Exosomes derived from circRNA Rtn4-modified BMSCs attenuate TNF-α-induced cytotoxicity and apoptosis in murine MC3T3-E1 cells by sponging miR-146a.

Bioscience reports·2026
Same journal

Evaluation of correlations between serum and urinary vitamin D metabolites using LC-MS/MS.

Bioscience reports·2026
Same journal

The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies.

Bioscience reports·2026
Same journal

A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells.

Bioscience reports·2026
Same journal

MCM2-7 proteins promote NF-κB transcriptional activity through cooperative promoter recruitment.

Bioscience reports·2026
See all related articles

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Pharmacology

Background:

  • Immunoliposomes are crucial for targeted drug delivery.
  • Pendant-type PEG-immunoliposomes (Type C) offer advanced targeting capabilities.
  • PEGylation influences liposome biodistribution and targeting efficacy.

Purpose of the Study:

  • To evaluate the targeting efficiency of pendant-type PEG-immunoliposomes (Type C) to two distinct anatomical sites: mouse lung endothelium and solid tumors.
  • To compare the performance of Type C immunoliposomes with conventional immunoliposomes (Type A).
  • To assess the potential of Type C immunoliposomes for enhanced drug delivery applications.

Main Methods:

  • Preparation of small unilamellar liposomes incorporating DSPE-PEG-COOH or DPPE-PEG-Mal.

Related Experiment Videos

  • Conjugation of specific antibodies (34A for lung endothelium, 21 B2 antibody/Fab' for tumor) to PEG-liposomes.
  • In vivo evaluation of lung binding and tumor accumulation in mouse models.
  • Assessment of RES uptake and circulation time.

    • Main Results:

    • 34A-conjugated Type C immunoliposomes showed significantly higher lung endothelial binding compared to Type A.
    • Fab'-conjugated Type C immunoliposomes exhibited low RES uptake and prolonged circulation.
    • Enhanced accumulation of Fab'-Type C immunoliposomes was observed in solid tumors, attributed to passive convective transport through leaky endothelium.

    Conclusions:

    • Pendant-type PEG-immunoliposomes (Type C) demonstrate superior targeting to both vascular endothelium and solid tumors.
    • Type C immunoliposomes possess favorable pharmacokinetic properties, including reduced RES uptake and extended circulation time.
    • These findings underscore the significant potential of Type C immunoliposomes for effective, target-specific drug delivery systems.